We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00683059
Recruitment Status : Completed
First Posted : May 23, 2008
Last Update Posted : October 17, 2016
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : June 2012
  Study Completion Date : June 2012